trulicity glp-1 Weight loss drugs don't work for everyone—here's why PCDS consensus statement: A strategy

Yang WL, Zhang CY, Ji WY, et al

Two placebo-controlled monotherapy studies, one of 18- and one of 24-week duration, included patients treated with JANUVIA 100 mg daily, JANUVIA 200 mg daily, and placebo

What Is Jennifer Hardy Jun 24 min read Oral Options: The Future of GLP-1s in a Pill The landscape of diabetes and obesity management made a significant transformation in 2026, driven by the development of oral glucagon-like peptide-1 (GLP-1) receptor agonists

From first order to final vial, we're with you

Yet, the common belief shared on the Internet is that as a more stable version, IGF-1 LR3 has a longer half-life than that of traditional insulin-like growth factor-1

In 2023 Lilly published results of its phase 2 trial for orforglipron, a once-daily oral drug which achieved up to 14.7% mean weight reduction at 36 weeks, and Pfizer has completed phase 2 trial for its oral drug danuglipron and is now optimising the formulation